Abstract
Policies consisting of or including prior authorisation (PA) of pharmaceutical prescriptions have been increasingly implemented by public and private insurers in the last decade, especially in the US, in order to control drug spending. We conducted a systematic review of published articles determining the effects of these policies on drug use, healthcare utilisation, healthcare expenditures and health outcomes.
A literature search was carried out in the electronic databases PubMed (which includes MEDLINE), EconLit, Web of Science and online sources including Google Scholar, from 1 January 1985 to 12 September 2006. Reference lists of retrieved articles were also searched. Peer-reviewed studies that provided empirical results about the impact of pharmaceutical PA policies, including randomised and non-randomised controlled trials, repeated measures studies, interrupted time series analyses and before-and-after studies were included.
Use of, and expenditure on, directly affected drugs per patient, and overall drug expenditure, significantly decreased after PA implementation, or increased after PA removal. Health outcome changes attributed to PA policies were not directly evaluated. In most cases, except for cimetidine, PA implementation was not associated with significant changes in the utilisation of other medical services. Although the literature indicates a reduction in drug expenditure and a nonnegative impact on use of other health services, policy recommendations still require improved study designs, and evidence cannot be easily transferred from one setting to another. The evidence still remains mainly limited to US Medicaid settings and to a small number of drug classes. There is a lack of consideration of implications of PA policies as heterogeneous interventions, outcome measurements require improvement, and there is a notable lack of evidence of medium-and long-term policy effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
OECD. OECD health data 2006: statistics and indicators for 30 countries. Paris: OECD, 2006
Kozma CM, Schulz RM, Dickson WM, et al. Economic impact of cost-containment strategies in third party programmes in the US. Pharmacoeconomics 1993; 4: 187–202
Carroll NV. How effectively do managed care organizations influence prescribing and dispensing decisions? Am J Manag Care 2002; 8: 1041–1054
Hamel MB, Epstein AM. Prior authorization programs for controlling drug spending. N Engl J Med 2004; 351: 2156–2158
Schneeweiss S, Maclure M, Carleton B, et al. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. BMJ 2004; 328 (7439): 560
Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff 2004; 23: 135–146
Haga A, Sverre JM. Pricing and reimbursement of pharmaceuticals in Norway. Eur J Health Econ 2002; 3: 215–220
Pedersen KM. Pricing and reimbursement of drugs in Denmark. Eur J Health Econ 2003; 4: 60–65
Rochaix L. De la Diffculte d’un Arbitrage entre Interet Collectif et Interets Individuels: un Dilemme de plus pour le Medecin. Journal d’Economie Medicale 1987; 4: 223–243
Rochaix L. The physician as perfect agent: a comment. Soc Sci Med 1998; 47: 355–356
Blomqvist A. The doctor as double agent: information asymmetry, health insurance, and medical care. J Health Econ 1991; 10: 411–432
Howard RC. The sentinel effect in an outpatient managed care setting. Prof Psychol Res Pr 1998; 29 (3): 262–268
Hernandez C, Casas A, Escarrabill J, et al. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. Eur Respir J 2003; 21: 58–67
Stuart B, Doshi JA, Briesacher B, et al. Impact of prescription coverage on hospital and physician costs: a case study of medicare beneficiaries with chronic obstructive pulmonary disease. Clin Ther 2004; 26: 1688–1699
Lichtenberg FR, Virabhak S. Pharmaceutical embodied technical progress, longevity, and quality of life: drugs as’ equipment for your health’ [working paper 9351]. Cambridge (MA): National Bureau of Economic Research, Inc., 2002
Cunningham PJ. Medicaid cost containment and access to prescription drugs. Health Aff 2005; 24: 780–789
Risser JA, Vash PD, Nieto L. Does prior authorization of sibutramine improve medication compliance or weight loss? Obes Res 2005; 13: 86–92
Meyer CM, Phipps R, Cooper D, et al. Pharmacy benefit forecast for a new interferon beta-1a for the treatment of multiple sclerosis: development of a first-line decision tool for pharmacy-budget planning using administrative claims data. J Manag Care Pharm 2003; 9: 168–174
Stacey J, Shaw E, Arledge MD, et al. Pharmacoeconomics modeling of prior-authorization intervention for COX-2 specific inhibitors in a 3-tier copay plan. J Manag Care Pharm 2003; 9: 327–334
Wertheimer AI, Santella TM. Effect of prior authorization and formulary limitation in community pharmacy practice and profitability. Drug Benefit Trends 2006; January: 36–49
MacKinnon NJ, Kumar R. Prior authorization programs: a critical review of the literature. J Manag Care Pharm 2001; 7: 297–302
Bloom BS, Jacobs J. Cost effects of restricting cost-effective therapy. Med Care 1985; 23: 872–880
Carroll NV, Smith JC, Berringer RA, et al. Evaluation of an automated system for prior authorization: a COX-2 inhibitor example. Am J Manag Care 2006; 12: 501–508
Delate T, Mager DE, Sheth J, et al. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care 2005; 11: 29–36
Fischer MA, Schneeweiss S, Avorn J, et al. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med 2004; 351: 2187–2194
Gleason PP, Williams C, Hrdy S, et al. Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program. Pharmacotherapy 2005; 25: 924–934
Hartung DM, Touchette DR, Ketchum KL, et al. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population. Clin Ther 2004; 26: 1518–1532
Kahan NR, Chinitz DP, Waitman DA, et al. When gatekeepers meet the sentinel: the impact of a prior authorization requirement for cefuroxime on the prescribing behaviour of community-based physicians. Br J Clin Pharmacol 2006; 61: 341–344
Kotzan JA, McMillan JA, Jankel CA, et al. Initial impact of a Medicaid prior authorization program for NSAID prescriptions. J Res Pharmaceut Econ 1993; 5: 25–41
McCombs JS, Shi L, Stimmel GL, et al. A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder. Clin Ther 2002; 24: 1939–1959
Momani AA, Madhavan SS, Nau DP. Impact of NSAIDs prior authorization policy on patients’ QoL. Ann Pharmacother 2002; 36: 1686–1691
Phillips CR, Larson LN. Evaluating the operational performance and financial effects of a drug prior authorization program. J Manag Care Pharm 1997; 3: 699–706
Roughead EE, Zhang F, Ross-Degnan D, et al. Differential effect of early or late implementation of prior authorization policies on the use of Cox II inhibitors. Med Care 2006; 44: 378–382
Smalley WE, Griffin MR, Fought RL, et al. Effect of a priorauthorization requirement on the use of nonsteroidal antiin-flammatory drugs by Medicaid patients. N Engl J Med 1995; 15: 1612–1617
Virabhak S, Shinogle JA. Physicians’ prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana. Am J Manag Care 2005; 11: SP14–SP20
Kotzan JA, Perri M III, Martin BC. Assessment of Medicaid prior-approval policies on prescription expenditures: market-share analysis of Medicaid and cash prescriptions. J Manag Care Pharm 1996; 2: 651–656
Lexchin J. Effects of restrictive formularies in the ambulatory care setting. Am J Manag Care 2001; 8: 69–76
Huskamp HA. Pharmaceutical cost management and access to psychotropic drugs: the US context. Int J Law Psychiatry 2005; 28: 484–495
White AC Jr, Atmar RL, Wilson J, et al. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997; 25: 230–239
Feldman SR, Fleischer AB, Chen GJ. Is prior authorization of topical tretinoin for acne cost effective? Am J Manag Care 1999; 5: 457–463
Fischer MA, Cheng H, Schneeweiss S, et al. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid (a policy review). Med Care 2006; 4: 658–663
Acknowledgements
The authors gratefully acknowledge helpful comments from Salvador Peiró, Paloma Fernández-Cano and two anonymous referees. Financial support is acknowledged from Merck, Sharp and Dohme de España S.A. and the Spanish Ministry of Education and Science under grant SEC2003-00036. The authors also benefited from support by way of an unrestricted educational grant from the Merck Company Foundation, the philanthropic arm of Merck & Co. Inc., Whitehouse Station, NJ, USA.
All authors declare that the funding sources did not play any role in the development of the article. The authors have no financial or other conflicts of interest that are directly relevant to the content of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Puig-Junoy, J., Moreno-Torres, I. Impact of Pharmaceutical Prior Authorisation Policies. Pharmacoeconomics 25, 637–648 (2007). https://doi.org/10.2165/00019053-200725080-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200725080-00002